- Home
- TSI vs NBTX Comparison
TSI vs NBTX Comparison
Compare TSI & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSI
- NBTX
- Stock Information
- Founded
- TSI 1987
- NBTX 2003
- Country
- TSI United States
- NBTX France
- Employees
- TSI N/A
- NBTX N/A
- Industry
- TSI Investment Managers
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- TSI Finance
- NBTX Health Care
- Exchange
- TSI Nasdaq
- NBTX Nasdaq
- Market Cap
- TSI 244.7M
- NBTX 235.6M
- IPO Year
- TSI N/A
- NBTX 2020
- Fundamental
- Price
- TSI $5.12
- NBTX $4.96
- Analyst Decision
- TSI
- NBTX Strong Buy
- Analyst Count
- TSI 0
- NBTX 2
- Target Price
- TSI N/A
- NBTX $11.50
- AVG Volume (30 Days)
- TSI 106.8K
- NBTX 12.7K
- Earning Date
- TSI 01-01-0001
- NBTX 10-22-2024
- Dividend Yield
- TSI 7.46%
- NBTX N/A
- EPS Growth
- TSI N/A
- NBTX N/A
- EPS
- TSI N/A
- NBTX N/A
- Revenue
- TSI N/A
- NBTX $45,220,186.00
- Revenue This Year
- TSI N/A
- NBTX N/A
- Revenue Next Year
- TSI N/A
- NBTX N/A
- P/E Ratio
- TSI N/A
- NBTX N/A
- Revenue Growth
- TSI N/A
- NBTX 526.17
- 52 Week Low
- TSI $4.48
- NBTX $4.14
- 52 Week High
- TSI $4.87
- NBTX $8.96
- Technical
- Relative Strength Index (RSI)
- TSI 55.85
- NBTX 46.18
- Support Level
- TSI $5.05
- NBTX $4.83
- Resistance Level
- TSI $5.10
- NBTX $5.36
- Average True Range (ATR)
- TSI 0.06
- NBTX 0.30
- MACD
- TSI -0.01
- NBTX -0.02
- Stochastic Oscillator
- TSI 75.00
- NBTX 28.81
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment, and others.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.